Oral drugs against COVID-19
Author:
Publisher
Deutscher Arzte-Verlag GmbH
Subject
General Medicine
Reference56 articles.
1. Owen DR, Allerton CMN, Anderson AS, et al.: An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 2021; 374: 1586–93
2. Mahase E: Covid-19: Pfizer’s Paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ 2021; 375: n2713
3. Hammond J, Leister-Tebbe H, et al.: Oral Nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med 2022; doi: 10.1056/NEJMoa2118542. Online ahead of print
4. Hsu A, Granneman GR, Bertz RJ: Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35: 275–91
5. Greenblatt DJ, Peters DE, Oleson LE, et al.: Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. Br J Clin Pharmacol 2009; 68: 920–7
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Ritonavir: 25 Years’ Experience of Concomitant Medication Management. A Narrative Review;Infectious Diseases and Therapy;2024-04-12
2. Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients;BMC Infectious Diseases;2024-01-03
3. Real-World Evidence of the Top 100 Prescribed Drugs in the USA and Their Potential for Drug Interactions with Nirmatrelvir; Ritonavir;The AAPS Journal;2023-07-20
4. Individuals at risk for severe COVID-19 in whom ritonavir-containing therapies are contraindicated or may lead to interactions with concomitant medications: a retrospective analysis of German health insurance claims data;Drugs in Context;2023-06-27
5. Understanding the Risk of Drug Interactions Between Ritonavir-Containing COVID-19 Therapies and Small-Molecule Kinase Inhibitors in Patients With Cancer;JCO Precision Oncology;2023-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3